# Patent

## Title
Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix

## Abstract

The present invention provides effective new methods and materials for maxillofacial bone augmentation, particularly alveolar ridge augmentation, that are free of problems associated with prior art methods. In one embodiment, these materials include human recombinant platelet derived growth factor (rhPDGF-BB) and a biocompatible matrix. In another embodiment, these materials include rhPDGF-BB, a deproteinized bone block or calcium phosphate, and a bioresorbable membrane. The use of these materials in the present method is effective in regenerating maxillofacial bones and facilitating achievement of stable osseointegrated implants. The mandible and maxilla are preferred bones for augmentation, and enhancement of the alveolar ridge is a preferred embodiment of the present invention.

## Background
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of application Ser. No. 11/159,533, filed Jun. 23, 2005, which is a continuation-in-part of application Ser. No. 10/965,319, filed Oct. 14, 2004, now abandoned. This application also claims the benefit of U.S. Provisional Patent Application No. 60/738,076, filed Nov. 17, 2005.


FIELD OF THE INVENTION
The present invention comprises compositions and methods for maxillofacial bone augmentation using compositions comprising a solution of PDGF and a biocompatible matrix, optionally including a biocompatible binder.
BACKGROUND OF THE INVENTION
Maxillofacial bone augmentation is needed in many situations including alveloar ridge augmentation (including horizontal and vertical ridge augmentation, in extraction sockets, in repair of bone sockets and deficiencies in the bony wall of the maxillary sinus.
Guided bone regeneration (GBR) is a regenerative procedure derived from guided tissue regeneration (GTR) around natural teeth and used for ridge augmentation prior to or in conjunction with osseointegrated implant placement. Originally, the biological principle of guided tissue regeneration was discovered by Nyman and Karring in the early 1980's. The surgical technique involves the placement of a cell occlusive barrier membrane to protect the blood clot and to create a secluded space around the bone defect to allow bone regeneration without competition from other tissues.
Schenk et al. (Int. J. Oral Maxillofac. Implants 1994; 9(1); 13-29) demonstrated how the newly regenerated bone progresses in a programmed sequence through a series of biological steps that closely parallel the pattern of normal bone growth and development. These findings have been confirmed by Simion et al. (Clin. Oral Implants Res. 1999; 10(2):73-84) with the same canine model using polytetrafluoroethylene (ePTFE) titanium-reinforced membranes. Evidence emerging from clinical studies also suggests that regenerated bone is capable of withstanding the occlusal loading exerted by functional forces, and is hence stable over time. (Mayfield et al. (Clin. Oral Implants Res. 1998; 9(5)297-302)).
GBR is well documented and studies demonstrate its high efficacy and predictability in horizontal and vertical ridge augmentation procedures. This last procedure, which is believed to be the most technically demanding of all GBR techniques, was first proposed by Simion et al. (Int. J. Periodontic Restorative Dent. 1994; 14(6):496:511) in 1994. It is indicated when bone height is insufficient for implant placement, long-term stability, or when prosthetic rehabilitation will result in excessively long crowns and an unfavorable implant/crown ratio.
A variety of materials are available for bone substitutes and membranes when applying the GBR principles. Human clinical studies have shown the possibility of successful vertical bone augmentation using e-PTFE membranes in combination with filling materials (autogenous bones (Tinti, et al., Int. J. Periodontics Restorative Dent. 1996; 16(3):220-9, Tinti, et al., Int. J. Periodontics Restorative Dent. 1998; 18(5):434-43)) and demineralized freeze-dried bone allograft (DFDBA), (Simion, et al., Int. J. Periodontics Restorative Dent. 1998; 18(1):8-23)).
One of the major issues concerning alveolar ridge augmentation procedures is the premature membrane exposure due to soft tissue dehiscence resulting in local infection and incomplete bone regeneration, jeopardizing the final results. In order to overcome these problems, the materials used and the surgical techniques applied in GBR have frequently been modified and adapted (Simion et al., Int. J. Periodontics Restorative Dent. 1994; 14(2):166-80, Simion et al, J. Clin. Periodontol. 1995; 22(4); 321-31).
Vertical ridge augmentation is needed for both the mandible and maxilla. Accordingly, what is needed are new methods and materials that are free of problems associated with prior art methods, and that are effective in augmenting bone, particularly augmentation maxillofacial bones, and particularly the alveolar ridge so that stable osseointegrated implants may be achieved.
SUMMARY OF THE INVENTION
The present invention provides effective new methods and compositions for bone augmentation, especially maxillofacial bone augmentation, that are free of problems associated with prior art methods. Such methods include, but are not limited to bone augmentation in the maxilla or mandible. Such bone augmentation sites may include but are not limited to alveolar ridge augmentation, repair of extraction sockets, sinus elevation, and deficiencies in the maxilla adjacent to the maxillary sinus. Alveolar ridge augmentation is one embodiment of the present invention and includes horizontal (lateral) and vertical ridge augmentation.
The compositions used in these methods include platelet derived growth factor (PDGF), such as recombinant human platelet derived growth factor (rhPDGF), a biocompatible matrix and, optionally, a resorbable membrane. The use of these compositions in the present method is effective in regenerating bone and in facilitating achievement of stable osseointegrated implants. While any bone may be augmented with the present invention, the mandible and maxilla are preferred bones for augmentation. Augmentation of alveolar ridges in the mandible and/or the maxilla is a preferred embodiment of the present invention.
In one aspect, a composition provided by the present invention for promoting bone augmentation comprises a solution comprising PDGF and a biocompatible matrix, wherein the solution is disposed in the biocompatible matrix. In some embodiments, PDGF is present in the solution in a concentration ranging from about 0.01 mg/ml to about 10 mg/ml, from about 0.05 mg/ml to about 5 mg/ml, or from about 0.1 mg/ml to about 1.0 mg/ml. The concentration of PDGF within the solution may be within any of the concentration ranges stated above.
In embodiments of the present invention, PDGF comprises PDGF homodimers and heterodimers, including PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, PDGF-DD, and mixtures and derivatives thereof. In one embodiment, PDGF comprises PDGF-BB. In another embodiment PDGF comprises a recombinant human (rh) PDGF such as rhPDGF-BB.
In some embodiments of the present invention, PDGF comprises PDGF fragments. In one embodiment rhPDGF-B comprises the following fragments: amino acid sequences 1-31, 1-32, 33-108, 33-109, and/or 1-108 of the entire B chain. The complete amino acid sequence (1-109) of the B chain of PDGF is provided in FIG. 15 of U.S. Pat. No. 5,516,896. It is to be understood that the rhPDGF compositions of the present invention may comprise a combination of intact rhPDGF-B (1-109) and fragments thereof. Other fragments of PDGF may be employed such as those disclosed in U.S. Pat. No. 5,516,896. In accordance with a preferred embodiment, the rhPDGF-BB comprises at least 65% of the entire amino acid sequence of rhPDGF-B (1-109).
A biocompatible matrix, according to some embodiments of the present invention, comprises a bone scaffolding material, such as a bone block. In some embodiments, the bone block may be demineralized. In some embodiments, a bone scaffolding material comprises calcium phosphate. Calcium phosphate, in one embodiment, comprises β-tricalcium phosphate.
In another aspect, the present invention provides a composition for promoting bone augmentation procedure comprising a PDGF solution disposed in a biocompatible matrix, wherein the biocompatible matrix comprises a bone block and a biocompatible binder. The PDGF solution may have a concentration of PDGF as described above. A bone scaffolding material, in some embodiments, comprises calcium phosphate. In an embodiment, calcium phosphate comprises β-tricalcium phosphate.
Moreover, a biocompatible binder, according to some embodiments of the present invention, comprises proteins, polysaccharides, nucleic acids, carbohydrates, synthetic polymers, or mixtures thereof. In one embodiment, a biocompatible binder comprises collagen. In another embodiment, a biocompatible binder comprises hyaluronic acid.
In another aspect, the present invention provides a kit comprising a biocompatible matrix in a first package and a solution comprising PDGF in a second package. In some embodiments, the solution comprises a predetermined concentration of PDGF. The concentration of the PDGF can be predetermined according to the surgical procedure being performed. Moreover, in some embodiments, the biocompatible matrix can be present in the kit in a predetermined amount. The amount of biocompatible matrix provided by a kit can be dependent on the surgical procedure being performed. In some embodiments, the second package containing the PDGF solution comprises a syringe. A syringe can facilitate disposition of the PDGF solution in the biocompatible matrix for application at a surgical site, such as a site of bone fusion in a bone augmentation procedure. In some embodiments, the kit contains a resorbable membrane which may be used in the methods of the present invention.
The present invention additionally provides methods for producing compositions for use in bone augmentation procedures as well as methods of performing bone augmentation procedures. In one embodiment, a method for producing a composition comprises providing a solution comprising PDGF, providing a biocompatible matrix, and disposing the solution in the biocompatible matrix.
In another embodiment, a method of performing a bone augmentation procedure comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to at least one site of desired bone augmentation. In some embodiments, the method comprises augmentation of the alveolar ridge of the mandible or maxilla. The augmented alveolar ridge may be prepared subsequently to receive an osseointegrated implant.
Accordingly, it is an object of the present invention to provide compositions comprising PDGF in a biocompatible matrix useful in facilitating bone augmentation.
It is an object of the present invention to provide compositions comprising PDGF in a biocompatible matrix useful in facilitating maxillofacial bone augmentation.
It is another object of the present invention to provide compositions comprising PDGF in a biocompatible matrix useful in facilitating bone augmentation in the maxilla or mandible.
Yet another object of the present invention is to provide compositions comprising PDGF in a biocompatible matrix useful in facilitating bone augmentation in the maxilla or mandible so that an implant may be inserted into the maxilla or mandible.
Another object of the present invention is to provide compositions comprising PDGF in a biocompatible matrix useful in facilitating alveolar ridge augmentation in the maxilla or mandible so that an implant may be stably inserted into the maxilla or mandible.
It is another object of the present invention to provide a method for vertical or horizontal bone augmentation, particularly in the maxilla and/or mandible.
Yet another object of the present invention is to provide a method for augmenting the alveolar ridge in the maxilla or mandible.
Another object of the present invention is to provide kits containing PDGF and a biocompatible matrix, optionally including a resorbable membrane.
These and other embodiments of the present invention are described in greater detail in the detailed description which follows. These and other objects, features, and advantages of the present invention will become apparent after review of the following detailed description of the disclosed embodiments and claims.



BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 presents radiographic results in 3 control animals receiving the deproteinized bovine block without PDGF, wherein the block was covered with the resorbable collagen membrane. The white, radiodense titanium implants (10) are placed in the mandible (20). The area (30) between the titanium implants is radiolucent and shows little or no bone growth. A nearby tooth (40) is shown.
FIG. 2 presents radiographic results in 4 experimental animals receiving the deproteinized bovine block with PDGF. The white, radiodense titanium implants (10) are placed in the mandible (20). The area (30) between the titanium implants is relatively radiodense and shows bone growth. A nearby tooth (40) is shown.
FIG. 3 presents radiographic results in 4 experimental animals receiving the deproteinized bovine block with PDGF, wherein the block was covered with the resorbable collagen membrane. The white radiodense titanium implants (10) are placed in the mandible (20). The area (30) between the titanium implants is relatively radiodense and shows bone growth. A nearby tooth (40) is shown.



DETAILED DESCRIPTION
The present invention provides effective new methods and compositions for bone augmentation, especially maxillofacial bone augmentation, that are free of problems associated with prior art methods. Such methods include, but are not limited to bone augmentation in the maxilla or mandible. Such bone augmentation sites may include but are not limited to alveolar ridge augmentation, repair of extraction sockets, sinus elevation, and deficiencies in the maxilla adjacent to the maxillary sinus. Alveolar ridge augmentation is one preferred embodiment of the present invention and includes horizontal (lateral) and vertical ridge augmentation. The term horizontal ridge is equivalent to lateral ridge and includes buccal, lingual and palatal ridges. The term vertical ridge includes the mandibular and maxillary vertical alveolar ridges.
In one embodiment, a composition for bone augmentation comprises a solution comprising PDGF and a biocompatible matrix, wherein the solution is disposed in the biocompatible matrix. In another embodiment, a composition comprises a PDGF solution disposed in a biocompatible matrix, wherein the biocompatible matrix comprises a bone scaffolding material and a biocompatible binder. In one embodiment PDGF is rhPDGF-BB in an acetate solution.
The present invention also provides a kit comprising a biocompatible matrix in a first package and a solution comprising PDGF in a second package which may act as a dispensing means. In some embodiments, the solution comprises a predetermined concentration of PDGF. In some embodiments, the concentration of PDGF is consistent with the values provided herein. The concentration of the PDGF can be predetermined according to the surgical procedure being performed. Moreover, in some embodiments, the biocompatible matrix can be present in the kit in a predetermined amount. The amount of biocompatible matrix provided by a kit can be dependent on the surgical procedure being performed. In specific embodiments the biocompatible matrix is a bone block or β-tricalcium phosphate. In some embodiments, the second package containing the PDGF solution comprises a dispensing means, such as a syringe. A syringe can facilitate disposition of the PDGF solution in the biocompatible matrix for application at a surgical site, such as a site of desired bone augmentation. In another embodiment, the kit also contains a resorbable membrane in another container.
Turning now to components that can be included in various embodiments of the present invention, compositions of the present invention comprise a solution comprising PDGF.
PDGF
PDGF plays an important role in regulating cell growth and division. PDGF, as with other growth factors, is operable to bind with the extracellular domains of receptor tyrosine kinases. The binding of PDGF to these transmembrane proteins switches on the kinase activity of their catalytic domains located on the cytosolic side of the membrane. By phosphorylating tyrosine residues of target proteins, the kinases induce a variety of cellular processes that include cell growth and extracellular matrix production.
In one aspect, a composition provided by the present invention comprises a solution comprising PDGF and a biocompatible matrix, wherein the solution is disposed in the biocompatible matrix. In some embodiments, PDGF is present in the solution in a concentration ranging from about 0.01 mg/ml to about 10 mg/ml, from about 0.05 mg/ml to about 5 mg/ml, or from about 0.1 mg/ml to about 1.0 mg/ml. PDGF may be present in the solution at any concentration within these stated ranges. In other embodiments, PDGF is present in the solution at any one of the following concentrations: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.2 mg/ml; about 0.25 mg/ml; about 0.3 mg/ml; about 0.35 mg/ml; about 0.4 mg/ml; about 0.45 mg/ml; about 0.5 mg/ml, about 0.55 mg/ml, about 0.6 mg/ml, about 0.65 mg/ml, about 0.7 mg/ml; about 0.75 mg/ml; about 0.8 mg/ml; about 0.85 mg/ml; about 0.9 mg/ml; about 0.95 mg/ml; or about 1.0 mg/ml. It is to be understood that these concentrations are simply examples of particular embodiments, and that the concentration of PDGF may be within any of the concentration ranges stated above.
Various amounts of PDGF may be used in the compositions of the present invention. Amounts of PDGF that could be used include amounts in the following ranges: about 1 ug to about 50 mg, about 10 ug to about 25 mg, about 100 ug to about 10 mg, and about 250 ug to about 5 mg. It is to be understood that the PDGF may be employed in conjunction with additional bone stimulating factors and/or drugs, for example bisphosphonates for inhibition of osteoclast activity.
The concentration of PDGF or other growth factors in embodiments of the present invention can be determined using methods known to one of ordinary skill in the art, for example by using an enzyme-linked immunoassay as described in U.S. Pat. Nos. 6,221,625, 5,747,273, and 5,290,708. Other assays known in the art may be used for determining PDGF concentration. When provided herein, the molar concentration of PDGF is determined based on the molecular weight (MW) of PDGF dimer (e.g., PDGF-BB; MW about 25 kDa).
In embodiments of the present invention, PDGF comprises PDGF homodimers and heterodimers, including PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, PDGF-DD, and mixtures and derivatives thereof. In one embodiment, PDGF comprises PDGF-BB. In another embodiment PDGF comprises a recombinant human (rh) PDGF, such as rhPDGF-BB.
PDGF, in some embodiments, can be obtained from natural sources. In other embodiments, PDGF can be produced by recombinant DNA techniques. In other embodiments, PDGF or fragments thereof may be produced using peptide synthesis techniques known to one of ordinary skill in the art, such as solid phase peptide synthesis. When obtained from natural sources, PDGF can be derived from biological fluids. Biological fluids, according to some embodiments, can comprise any treated or untreated fluid associated with living organisms including blood
Biological fluids, in another embodiment, can also comprise blood components including platelet concentrate (PC), apheresed platelets, platelet-rich plasma (PRP), plasma, serum, fresh frozen plasma (FFP), and buffy coat (BC). Biological fluids, in a further embodiment, can comprise platelets separated from plasma and resuspended in a physiological fluid.
When produced by recombinant DNA techniques, a DNA sequence encoding a single monomer (e.g., PDGF B-chain or A-chain), in some embodiments, can be inserted into cultured prokaryotic or eukaryotic cells for expression to subsequently produce the homodimer (e.g. PDGF-BB or PDGF-AA). In other embodiments, a PDGF heterodimer can be generated by inserting DNA sequences encoding for both monomeric units of the heterodimer into cultured prokaryotic or eukaryotic cells and allowing the translated monomeric units to be processed by the cells to produce the heterodimer (e.g. PDGF-AB). Commercially available GMP recombinant PDGF-BB can be obtained commercially from Chiron Corporation (Emeryville, Calif.). Research grade rhPDGF-BB can be obtained from multiple sources including R&D Systems, Inc. (Minneapolis, Minn.), BD Biosciences (San Jose, Calif.), and Chemicon, International (Temecula, Calif.).
In some embodiments of the present invention, PDGF comprises PDGF fragments. In one embodiment rhPDGF-B comprises the following fragments: amino acid sequences 1-31, 1-32, 33-108, 33-109, and/or 1-108 of the entire B chain. The complete amino acid sequence (1-109) of the B chain of PDGF is provided in FIG. 15 of U.S. Pat. No. 5,516,896. It is to be understood that the rhPDGF compositions of the present invention may comprise a combination of intact rhPDGF-B (1-109) and fragments thereof. Other fragments of PDGF may be employed such as those disclosed in U.S. Pat. No. 5,516,896. In accordance with a preferred embodiment, the rhPDGF-BB comprises at least 65% of intact rhPDGF-B (1-109).
In some embodiments of the present invention, PDGF can be purified. Purified PDGF, as used herein, comprises compositions having greater than about 95% by weight PDGF prior to incorporation in solutions of the present invention. The solution may be any pharmaceutically acceptable solution. In other embodiments, the PDGF can be substantially purified. Substantially purified PDGF, as used herein, comprises compositions having about 5% to about 95% by weight PDGF prior to incorporation into solutions of the present invention. In one embodiment, substantially purified PDGF comprises compositions having about 65% to about 95% by weight PDGF prior to incorporation into solutions of the present invention. In other embodiments, substantially purified PDGF comprises compositions having about 70% to about 95%, about 75% to about 95%, about 80% to about 95%, about 85% to about 95%, or about 90% to about 95%, by weight PDGF, prior to incorporation into solutions of the present invention. Purified PDGF and substantially purified PDGF may be incorporated into scaffolds and binders.
In a further embodiment, PDGF can be partially purified. Partially purified PDGF, as used herein, comprises compositions having PDGF in the context of platelet rich plasma (PRP), fresh frozen plasma (FFP), or any other blood product that requires collection and separation to produce PDGF. Embodiments of the present invention contemplate that any of the PDGF isoforms provided herein, including homodimers and heterodimers, can be purified or partially purified. Compositions of the present invention containing PDGF mixtures may contain PDGF isoforms or PDGF fragments in partially purified proportions. Partially purified and purified PDGF, in some embodiments, can be prepared as described in U.S. patent application Ser. Nos. 10/965,319 and 11/159,533 (Publication No: 20060084602).
In some embodiments, solutions comprising PDGF are formed by solubilizing PDGF in one or more buffers. Buffers suitable for use in PDGF solutions of the present invention can comprise, but are not limited to, carbonates, phosphates (e.g. phosphate buffered saline), histidine, acetates (e.g. sodium acetate), acidic buffers such as acetic acid and HCI, and organic buffers such as lysine, Tris buffers (e.g. tris(hydroxymethyl)aminoethane), N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), and 3-(N-morpholino) propanesulfonic acid (MOPS). Buffers can be selected based on biocompatibility with PDGF and the buffer's ability to impede undesirable protein modification. Buffers can additionally be selected based on compatibility with host tissues. In a preferred embodiment, sodium acetate buffer is used. The buffers may be employed at different molarities, for example about 0.1 mM to about 100 mM, about 1 mM to about 50 mM, about 5 mM to about 40 mM, about 10 mM to about 30 mM, or about 15 mM to about 25 mM, or any molarity within these ranges. In one embodiment, an acetate buffer is employed at a molarity of about 20 mM.
In another embodiment, solutions comprising PDGF are formed by solubilizing lyophilized PDGF in water, wherein prior to solubilization the PDGF is lyophilized from an appropriate buffer.
Solutions comprising PDGF, according to embodiments of the present invention, can have a pH ranging from about 3.0 to about 8.0. In one embodiment, a solution comprising PDGF has a pH ranging from about 5.0 to about 8.0, more preferably about 5.5 to about 7.0, most preferably about 5.5 to about 6.5, or any value within these ranges. The pH of solutions comprising PDGF, in some embodiments, can be compatible with the prolonged stability and efficacy of PDGF or any other desired biologically active agent. PDGF is generally more stable in an acidic environment. Therefore, in accordance with one embodiment the present invention comprises an acidic storage formulation of a PDGF solution. In accordance with this embodiment, the PDGF solution preferably has a pH from about 3.0 to about 7.0, and more preferably from about 4.0 to about 6.5. The biological activity of PDGF, however, can be optimized in a solution having a neutral pH range. Therefore, in a further embodiment, the present invention comprises a neutral pH formulation of a PDGF solution. In accordance with this embodiment, the PDGF solution preferably has a pH from about 5.0 to about 8.0, more preferably about 5.5 to about 7.0, most preferably about 5.5 to about 6.5. In accordance with a method of the present invention, an acidic PDGF solution is reformulated to a neutral pH composition, wherein such composition is then used to treat bone in order to promote growth. In accordance with a preferred embodiment of the present invention, the PDGF utilized in the solutions is rhPDGF-BB.
The pH of solutions comprising PDGF, in some embodiments, can be controlled by the buffers recited herein. Various proteins demonstrate different pH ranges in which they are stable. Protein stabilities are primarily reflected by isoelectric points and charges on the proteins. The pH range can affect the conformational structure of a protein and the susceptibility of a protein to proteolytic degradation, hydrolysis, oxidation, and other processes that can result in modification to the structure and/or biological activity of the protein.
In some embodiments, solutions comprising PDGF can further comprise additional components. In other embodiments, solutions comprising PDGF can further comprise cell culture media, other stabilizing proteins such as albumin, antibacterial agents, protease inhibitors (e.g., EDTA, EGTA, aprotinin, EACA, etc.) and/or other growth factors such as FGFs, EGF, TGFs, KGFs, IGFs BMPs, or other PDGFs including PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC and/or PDGF-DD.
In addition to solutions comprising PDGF, compositions of the present invention also comprise a biocompatible matrix in which to dispose the PDGF solutions and may also comprise a biocompatible binder either with or without addition of a biocompatible matrix.
Biocompatible Matrix
Bone Scaffolding Material
A biocompatible matrix, according to embodiments of the present invention, comprises a bone scaffolding material. The bone scaffolding material provides the framework or scaffold for new bone and tissue growth to occur.
A bone scaffolding material, in some embodiments, comprises a bone block. Bone blocks may be obtained from different sources. In one embodiment, a deproteinized bovine bone block is used (Bio-Oss Block, Geistlich biomaterials). Deproteinized bovine bone is a xenogenic material processed to remove the organic component. Its efficacy has been well demonstrated both in periodontal and implant literature in terms of long-term stability (Sarton et al., Clin Oral implants Res. 2003 June: 14(3):369-72). Deproteinized bone may be obtained from other species, including but not limited to humans, and used in the present invention.
Other matrix materials may be used in the present invention, such as autologous cortical, cancellous and cortico-cancellous bone blocks and particulate graft having an average diameter of 0.1 mm to 100 mm. Further, allogeneic, xenogenic, cortical, cancellous and cortico-cancellous bone blocks and pieces having an average diameter of 0.1 mm to 100 mm may also be used in the present invention.
In some embodiments, a bone scaffolding material comprises porous structure. Porous bone scaffolding materials, according to some embodiments, can comprise pores having diameters ranging from about 1 μm to about 1 mm. In one embodiment, a bone scaffolding material comprises macropores having diameters ranging from about 100 μm to about 1 mm. In another embodiment, a bone scaffolding material comprises mesopores having diameters ranging from about 10 μm to about 100 μm. In a further embodiment, a bone scaffolding material comprises micropores having diameters less than about 10 μm. Embodiments of the present invention contemplate bone scaffolding materials comprising macropores, mesopores, and micropores or any combination thereof.
A porous bone scaffolding material, in one embodiment, has a porosity greater than about 25%. In another embodiment, a porous bone scaffolding material has a porosity greater than about 50%. In a further embodiment, a porous bone scaffolding material has a porosity greater than about 90%.
A bone scaffolding material, in some embodiments, comprises at least one calcium phosphate. In other embodiments, a bone scaffolding material can comprise a plurality of calcium phosphates. Calcium phosphates suitable for use as a bone scaffolding material, in embodiments of the present invention, have a calcium to phosphorus atomic ratio ranging from 0.5 to 2.0.
Non-limiting examples of calcium phosphates suitable for use as bone scaffolding materials comprise amorphous calcium phosphate, monocalcium phosphate monohydrate (MCPM), monocalcium phosphate anhydrous (MCPA), dicalcium phosphate dihydrate (DCPD), dicalcium phosphate anhydrous (DCPA), octacalcium phosphate (OCP), α-tricalcium phosphate, β-tricalcium phosphate, hydroxyapatite (OHAp), poorly crystalline hydroxapatite, tetracalcium phosphate (TTCP), heptacalcium decaphosphate, calcium metaphosphate, calcium pyrophosphate dihydrate, calcium pyrophosphate, carbonated calcium phosphate, or mixtures thereof.
In some embodiments, a bone scaffolding material comprises a plurality of particles. A bone scaffolding material, for example, can comprise a plurality of calcium phosphate particles. Bone scaffolding particles, in one embodiment, have an average diameter ranging from about 1 μm to about 5 mm. Bone scaffolding particles, in one embodiment, have an average diameter ranging from about 1 μm to about 2 mm. Bone scaffolding particles, in one embodiment, have an average diameter ranging from about 1 mm to about 2 mm. In other embodiments, particles have an average diameter ranging from about 250 μm to about 1000 μm. In other embodiments, particles have an average diameter ranging from about 250 μm to about 750 μm. Bone scaffolding particles, in another embodiment, have an average diameter ranging from about 100 μm to about 300 μm. Bone scaffolding particles, in another embodiment, have an average diameter ranging from about 100 μm to about 400 μm. In a further embodiment, the particles have an average diameter ranging from about 75 μm to about 300 μm. In additional embodiments, bone scaffolding particles have an average diameter less than about 1 μm and, in some cases, less than about 1 mm.
Bone scaffolding materials, according to some embodiments, can be provided in a shape suitable for implantation (e.g., a sphere, a cylinder, or a block). In other embodiments, bone scaffolding materials are moldable. Moldable bone scaffolding materials can facilitate efficient placement of compositions of the present invention in and around target sites in bone. In some embodiments, moldable bone scaffolding materials can be applied to sites of desired bone augmentation with a spatula or equivalent device. In some embodiments, bone scaffolding materials are flowable. Flowable bone scaffolding materials, in some embodiments, can be applied to sites of bone fusion through a syringe and needle or cannula. In some embodiments, bone scaffolding materials harden in vivo.
In some embodiments, bone scaffolding materials are bioresorbable. A bone scaffolding material, in one embodiment, can be resorbed within one year of in vivo implantation. In another embodiment, a bone scaffolding material can be resorbed within 1, 3, 6, or 9 months of in vivo implantation. Bioresorbability will be dependent on: (1) the nature of the matrix material (i.e., its chemical make up, physical structure and size); (2) the location within the body in which the matrix is placed; (3) the amount of matrix material that is used; (4) the metabolic state of the patient (diabetic/non-diabetic, osteoporotic, smoker, old age, steroid use, etc.); (5) the extent and/or type of injury treated; and (6) the use of other materials in addition to the matrix such as other bone anabolic, catabolic and anti-catabolic factors.
Bone Scaffolding Comprising β-Tricalcium Phosphate
A bone scaffolding material for use as a biocompatible matrix can comprise β-tricalcium phosphate (β-TCP). β-TCP, according to some embodiments, can comprise a porous structure having multidirectional and interconnected pores of varying diameters. The porous structure of β-TCP, in one embodiment, comprises macropores having diameters ranging from about 100 μm to about 1 mm, mesopores having diameters ranging from about 10 μm to about 100 μm, and micropores having diameters less than about 10 μm. Macropores and micropores of the β-TCP can facilitate osteoinduction and osteoconduction while macropores, mesopores and micropores can permit fluid communication and nutrient transport to support bone regrowth throughout the β-TCP biocompatible matrix.
In comprising a porous structure, β-TCP, in some embodiments, can have a porosity greater than 25%. In other embodiments, β-TCP can have a porosity greater than 50%. In a further embodiment, β-TCP can have a porosity greater than 90%.
In some embodiments, a bone scaffolding material comprises β-TCP particles. β-TCP particles, in one embodiment, have an average diameter ranging from about 1 μm to about 5 mm. β-TCP particles, in one embodiment, have an average diameter ranging from about 1 μm to about 2 mm. β-TCP particles, in one embodiment, have an average diameter ranging from about 1 mm to about 2 mm. In other embodiments, β-TCP particles have an average diameter ranging from about 250 μm to about 1000 μm. In other embodiments, β-TCP particles have an average diameter ranging from about 250 μm to about 750 μm. In another embodiment, β-TCP particles have an average diameter ranging from about 100 μm to about 400 μm. In another embodiment, β-TCP particles have an average diameter ranging from about 100 μm to about 300 μm. In a further embodiment, β-TCP particle have an average diameter ranging from about 75 μm to about 300 μm. In additional embodiments, β-TCP particles have an average diameter less than 25 μm and, in some cases, an average diameter less than lmm. In additional embodiments, β-TCP particles have an average diameter less than 1 μm and, in some cases, an average diameter less than 1 mm.
A biocompatible matrix comprising a β-TCP bone scaffolding material, in some embodiments, can be provided in a shape suitable for implantation (e.g., a sphere, a cylinder, or a block). In other embodiments, a β-TCP bone scaffolding material can be moldable thereby facilitating placement of the matrix in sites of desired bone augmentation such as the maxilla or mandible. Flowable matrices may be applied through syringes, tubes, or spatulas.
A β-TCP bone scaffolding material, according to some embodiments, is bioresorbable. In one embodiment, a β-TCP bone scaffolding material can be at least 75% resorbed one year subsequent to in vivo implantation. In another embodiment, a β-TCP bone scaffolding material can be greater than 90% resorbed one year subsequent to in vivo implantation.
Bone Scaffolding Material and Biocompatible Binder
In another embodiment, a biocompatible matrix comprises a bone scaffolding material and a biocompatible binder. Bone scaffolding materials in embodiments of a biocompatible matrix further comprising a biocompatible binder are consistent with those provided hereinabove.
Biocompatible binders, according to some embodiments, can comprise materials operable to promote cohesion between combined substances. A biocompatible binder, for example, can promote adhesion between particles of a bone scaffolding material in the formation of a biocompatible matrix. In certain embodiments, the same material may serve as both a scaffolding material and a binder if such material acts to promote cohesion between the combined substances and provides a framework for new bone growth to occur.
Biocompatible binders, in some embodiments, can comprise collagen, collagen of various degrees of cross-linking, polysaccharides, nucleic acids, carbohydrates, proteins, polypeptides, poly(α-hydroxy acids), poly(lactones), poly(amino acids), poly(anhydrides), poly(orthoesters), poly(anhydride-co-imides), poly(orthocarbonates), poly(α-hydroxy alkanoates), poly(dioxanones), poly(phosphoesters), polylactic acid, poly(L-lactide) (PLLA), poly(D,L-lactide) (PDLLA), polyglycolide (PGA), poly(lactide-co-glycolide (PLGA), poly(L-lactide-co-D,L-lactide), poly(D,L-lactide-co-trimethylene carbonate), polyglycolic acid, polyhydroxybutyrate (PHB), poly(ε-caprolactone), poly(δ-valerolactone), poly(γ-butyrolactone), poly(caprolactone), polyacrylic acid, polycarboxylic acid, poly(allylamine hydrochloride), poly(diallyldimethylammonium chloride), poly(ethyleneimine), polypropylene fumarate, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene, polyurethanes, polymethylmethacrylate, carbon fibers, poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethyloxazoline), poly(ethylene oxide)-co-poly(propylene oxide) block copolymers, poly(ethylene terephthalate)polyamide, and copolymers and mixtures thereof.
Biocompatible binders, in other embodiments, can comprise alginic acid, arabic gum, guar gum, xantham gum, gelatin, chitin, chitosan, chitosan acetate, chitosan lactate, chondroitin sulfate, lecithin, N,O-carboxymethyl chitosan, phosphatidylcholine derivatives, a dextran (e.g., α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, or sodium dextran sulfate), fibrin glue, glycerol, hyaluronic acid, sodium hyaluronate, a cellulose (e.g., methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, or hydroxyethyl cellulose), a glucosamine, a proteoglycan, a starch (e.g., hydroxyethyl starch or starch soluble), lactic acid, a pluronic acid, sodium glycerophosphate, glycogen, a keratin, silk, and derivatives and mixtures thereof, and binders known to one of ordinary skill in the art for use in orthopedic applications.
In some embodiments, a biocompatible binder is water-soluble. A water-soluble binder can dissolve from the biocompatible matrix shortly after its implantation, thereby introducing macroporosity into the biocompatible matrix. Macroporosity, as discussed herein, can increase the osteoconductivity of the implant material by enhancing the access and, consequently, the remodeling activity of the osteoclasts and osteoblasts at the implant site.
In some embodiments, a biocompatible binder can be present in a biocompatible matrix in an amount ranging from about 5 weight percent to about 50 weight percent of the matrix. In other embodiments, a biocompatible binder can be present in an amount ranging from about 10 weight percent to about 40 weight percent of the biocompatible matrix. In another embodiment, a biocompatible binder can be present in an amount ranging from about 15 weight percent to about 35 weight percent of the biocompatible matrix. In a further embodiment, a biocompatible binder can be present in an amount of about 20 weight percent of the biocompatible matrix.
A biocompatible matrix comprising a bone scaffolding material and a biocompatible binder, according to some embodiments, can be flowable, moldable, and/or extrudable. In such embodiments, a biocompatible matrix can be in the form of a paste or putty. A biocompatible matrix in the form of a paste or putty, in one embodiment, can comprise particles of a bone scaffolding material adhered to one another by a biocompatible binder.
A biocompatible matrix in paste or putty form can be molded into the desired implant shape or can be molded to the contours of the implantation site. In one embodiment, a biocompatible matrix in paste or putty form can be injected into an implantation site with a syringe or cannula.
In some embodiments, a biocompatible matrix in paste or putty form does not harden and retains a flowable and moldable form subsequent to implantation. In other embodiments, a paste or putty can harden subsequent to implantation, thereby reducing matrix flowability and moldability.
A biocompatible matrix comprising a bone scaffolding material and a biocompatible binder, in some embodiments, can also be provided in a predetermined shape including a block, sphere, or cylinder or any desired shape, for example a shape defined by a mold or a site of application.
A biocompatible matrix comprising a bone scaffolding material and a biocompatible binder, in some embodiments, is bioresorbable. A biocompatible matrix, in such embodiments, can be resorbed within one year of in vivo implantation. In another embodiment, a biocompatible matrix comprising a bone scaffolding material and a biocompatible binder can be resorbed within 1, 3, 6, or 9 months of in vivo implantation. Bioresorbablity will be dependent on: (1) the nature of the matrix material (i.e., its chemical make up, physical structure and size); (2) the location within the body in which the matrix is placed; (3) the amount of matrix material that is used; (4) the metabolic state of the patient (diabetic/non-diabetic, osteoporotic, smoker, old age, steroid use, etc.); (5) the extent and/or type of injury treated; and (6) the use of other materials in addition to the matrix such as other bone anabolic, catabolic and anti-catabolic factors.
Biocompatible Matrix Comprising β-TCP and Collagen
In some embodiments, a biocompatible matrix can comprise a β-TCP bone scaffolding material and a biocompatible collagen binder. β-TCP bone scaffolding materials suitable for combination with a collagen binder are consistent with those provided hereinabove.
A collagen binder, in some embodiments, can comprise any type of collagen, including Type I, Type II, and Type III collagens. The collagen used may also be cross-linked to various extents. In one embodiment, a collagen binder comprises a mixture of collagens, such as a mixture of Type I and Type II collagen. In other embodiments, a collagen binder is soluble under physiological conditions. Other types of collagen present in bone or musculoskeletal tissues may be employed. Recombinant, synthetic and naturally occurring forms of collagen may be used in the present invention.
A biocompatible matrix, according to some embodiments, can comprise a plurality of β-TCP particles adhered to one another with a collagen binder. In one embodiment, β-TCP particles suitable for combination with a collagen binder have an average diameters as described above.
β-TCP particles, in some embodiments, can be adhered to one another by the collagen binder so as to produce a biocompatible matrix having a porous structure. In some embodiments, a biocompatible matrix comprising β-TCP particles and a collagen binder can comprise pores having diameters ranging from about 1 μm to about 1 mm. A biocompatible matrix comprising β-TCP particles and a collagen binder can comprise macropores having diameters ranging from about 100 μm to about 1 mm, mesopores having diameters ranging from about 10 μm to 100 μm, and micropores having diameters less than about 10 μm.
A biocompatible matrix comprising β-TCP particles and a collagen binder can have a porosity greater than about 25%. In another embodiment, the biocompatible matrix can have a porosity greater than about 50%. In a further embodiment, the biocompatible matrix can have a porosity greater than about 90%.
A biocompatible matrix comprising β-TCP particles, in some embodiments, can comprise a collagen binder in an amount ranging from about 5 weight percent to about 50 weight percent of the matrix. In other embodiments, a collagen binder can be present in an amount ranging from about 10 weight percent to about 40 weight percent of the biocompatible matrix. In another embodiment, a collagen binder can be present in an amount ranging from about 15 weight percent to about 35 weight percent of the biocompatible matrix. In a further embodiment, a collagen binder can be present in an amount of about 20 weight percent of the biocompatible matrix.
A biocompatible matrix comprising β-TCP particles and a collagen binder, according to some embodiments, can be flowable, moldable, and/or extrudable. In such embodiments, the biocompatible matrix can be in the form of a paste or putty. A paste or putty can be molded into the desired implant shape or can be molded to the contours of the implantation site. In one embodiment, a biocompatible matrix in paste or putty form comprising β-TCP particles and a collagen binder can be injected into an implantation site with a syringe or cannula.
In some embodiments, a biocompatible matrix in paste or putty form comprising β-TCP particles and a collagen binder can retain a flowable and moldable form when implanted. In other embodiments, the paste or putty can harden subsequent to implantation, thereby reducing matrix flowability and moldability.
A biocompatible matrix comprising β-TCP particles and a collagen binder, in some embodiments, can be provided in a predetermined shape such as a block, sphere, or cylinder.
A biocompatible matrix comprising β-TCP particles and a collagen binder can be resorbable. In one embodiment, a biocompatible matrix comprising β-TCP particles and a collagen binder can be at least 75% resorbed one year subsequent to in vivo implantation. In another embodiment, a biocompatible matrix comprising β-TCP particles and a collagen binder can be greater than 90% resorbed one year subsequent to in vivo implantation.
A solution comprising PDGF can be disposed in a biocompatible matrix to produce a composition for promoting bone augmentation, particularly of the vertical alveolar ridge according to embodiments of the present invention.
Resorbable Membrane
In order to improve treatment outcome and predictability of GBR procedures, complications encountered in such procedures should be reduced or eliminated. One of the observed and most threatening negative outcomes that may occur is early membrane exposure with bacterial contamination resulting in failure or incomplete success of GBR procedure (Simion et al., Int. J. Periodontics Restorative Dent. 1994; 14(2):166-80, Simion et al., J. Clin Periodentol. 1995; 22(4):321-31, Simion et al., Clin. Oral Implants Res. 1997; 8(1):23-31). This is particularly evident when using non-resorbable membranes, e.g. GORE-TEX®. The main advantage in using these membranes is the possibility to keep them in situ for the needed time period for the healing process to occur. Resorbable membranes made, for example, of natural or synthetic polymers such as collagen or polylactides and/or polyglycolides may also be used. These membranes have the advantage of gradually absorbing over time thus eliminating the need to surgically remove them. In the present investigation described in Example 1, collagen membranes were used. These membranes must be wetted in order to conform properly to the surgical site. The results in Example 1 showed no difference in bone augmentation surrounding the titanium implants between animals receiving bovine blocks with PDGF and animals receiving bovine blocks with PDGF and the collagen resorbable membrane. Accordingly, resorbable membranes may optionally be employed in the practice of the present invention.
Disposing PDGF Solution in a Biocompatible Matrix
The present invention provides methods for producing compositions for use in bone augmentation procedures. In one embodiment, a method for producing a composition for promoting the fusion of bone comprises providing a solution comprising PDGF, providing a biocompatible matrix, and disposing the solution in the biocompatible matrix. PDGF solutions and biocompatible matrices suitable for combination are consistent with those described hereinabove.
In one embodiment, a PDGF solution can be disposed in a biocompatible matrix by soaking the biocompatible matrix in the PDGF solution. A PDGF solution, in another embodiment, can be disposed in a biocompatible matrix by injecting the biocompatible matrix with the PDGF solution. In some embodiments, injecting a PDGF solution can comprise disposing the PDGF solution in a syringe and expelling the PDGF solution into the biocompatible matrix to saturate the biocompatible matrix.
The biocompatible matrix, according to some embodiments, can be in a predetermined shape, such as a brick or cylinder, prior to receiving a PDGF solution. Subsequent to receiving a PDGF solution, the biocompatible matrix can have a paste or putty form that is flowable, extrudable, and/or injectable. In other embodiments, the biocompatible matrix can already demonstrate a flowable paste or putty form prior to receiving a solution comprising PDGF.
Compositions Further Comprising Biologically Active Agents
Compositions for promoting and/or facilitating bone augmentation, according to some embodiments, can further comprise one or more biologically active agents in addition to PDGF. Biologically active agents that can be incorporated into compositions of the present invention in addition to PDGF can comprise organic molecules, inorganic materials, proteins, peptides, nucleic acids (e.g., genes, gene fragments, gene regulatory sequences, and antisense molecules), nucleoproteins, polysaccharides (e.g., heparin), glycoproteins, and lipoproteins. Non-limiting examples of biologically active compounds that can be incorporated into compositions of the present invention, including, e.g., anti-cancer agents, antibiotics, analgesics, anti-inflammatory agents, immunosuppressants, enzyme inhibitors, antihistamines, hormones, muscle relaxants, prostaglandins, trophic factors, osteoinductive proteins, growth factors, and vaccines, are disclosed in U.S. patent application Ser. Nos. 10/965,319 and 11/159,533 (Publication No: 20060084602). Preferred biologically active compounds that can be incorporated into compositions of the present invention include osteoinductive factors such as insulin-like growth factors, fibroblast growth factors, or other PDGFs. In accordance with other embodiments, biologically active compounds that can be incorporated into compositions of the present invention preferably include osteoinductive and osteostimulatory factors such as bone morphogenetic proteins (BMPs), BMP mimetics, calcitonin, calcitonin mimetics, statins, statin derivatives, or parathyroid hormone. Preferred factors also include protease inhibitors, as well as osteoporotic treatments that decrease bone resorption including bisphosphonates, and antibodies to receptor activator of NF-kB ligand (RANK) ligand.
Standard protocols and regimens for delivery of additional biologically active agents are known in the art. Additional biologically active agents can be introduced into compositions of the present invention in amounts that allow delivery of an appropriate dosage of the agent to the implant site. In most cases, dosages are determined using guidelines known to practitioners and applicable to the particular agent in question. The amount of an additional biologically active agent to be included in a composition of the present invention can depend on such variables as the type and extent of the condition, the overall health status of the particular patient, the formulation of the biologically active agent, release kinetics, and the bioresorbability of the biocompatible matrix. Standard clinical trials may be used to optimize the dose and dosing frequency for any particular additional biologically active agent.
A composition for promoting bone augmentation, according to some embodiments, can further comprise the addition of other bone grafting materials with PDGF including autologous bone marrow, autologous platelet extracts, and synthetic bone matrix materials.
Methods of Performing Bone Augmentation Procedures
The present invention also provides methods of performing bone augmentation procedures. In one embodiment, a method of performing a bone augmentation procedure comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix, and optionally containing a biocompatible binder, and applying the composition to at least one site of desired bone augmentation. In some embodiments, a method of performing a bone augmentation procedure comprises applying the composition to at least one site of bone augmentation in the maxilla or mandible. A composition comprising a PDGF solution disposed in a biocompatible matrix, for example, can be packed into a site of desired bone augmentation in the maxilla or mandible. In another embodiment, the PDGF solution is applied to the implantation site before, and optionally after placement of the composition comprising the PDGF solution disposed in the biocompatible matrix into the implantation site. By enhancing the deposition of bone in the maxilla or mandible, the alveolar ridge may be enhanced so as to subsequently receive an implant. Such implants may be used for a variety of purposes, including as a support for a tooth or other dental device, and for various oral and maxillofacial applications, including extraction sockets, sinus elevation, and ridge augmentation.
Kits
The present invention also provides a kit comprising a biocompatible matrix in a first container and a solution comprising PDGF in a second container which may act as a dispensing means. In some embodiments, the solution comprises a predetermined concentration of PDGF. In some embodiments, the concentration of PDGF is consistent with the values provided herein. The concentration of the PDGF can be predetermined according to the surgical procedure being performed. Moreover, in some embodiments, the biocompatible matrix can be present in the kit in a predetermined amount. The amount of biocompatible matrix provided in a kit can be dependent on the surgical procedure being performed. In some embodiments, the second package containing the PDGF solution comprises a dispensing means, such as a syringe or a compressible tube. A syringe or a compressible tube can facilitate disposition of the PDGF solution in the biocompatible matrix for application at a surgical site, such as a site of desired bone augmentation. In another embodiment, the kit also contains a bioresorbable membrane in another container. In one embodiment, the bioresorbable membrane comprises a collagen bioresorbable membrane.
In one embodiment, the kit contains a first container with a biocompatible matrix. In one embodiment the biocompatible matrix is calcium phosphate. In a preffered embodiment the biocompatible matrix is β-tricalcium phosphate. In another preferred embodiment the biocompatible matrix is a bone block, for example an xenogenic, autologous cortical, cancellous or cortico-cancellous bone blocks. Such bone blocks may be demineralized as described previously in this application. The allogeneic, xenogenic, cortical, cancellous and cortico-cancellous bone blocks and pieces placed in the first container may have an average diameter of 0.1 mm to 100 mm. The specific size of the bone block in the kit depends on the specific application.
The kit contains a second container comprising PDGF. In one embodiment, the PDGF may be present in a dry form, for example as a powder or a lyophilized form at a selected amount appropriate for use in augmenting bone. When PDGF is present in dry form, another container may be present in the kit containing the solution for solvation of the PDGF before application to the biocompatible matrix. In another embodiment, the PDGF may be present in solution as described previously in this application. This second container may take the form of a dispensing container, such as a syringe or a compressible tube, to facilitate delivery of the PDGF in solution to the biocompatible matrix. While the PDGF may be any PDGF, as recited earlier in this application, in a preferred embodiment the PDGF is PDGF-BB. In another preferred embodiment, the PDGF-BB is rhPDGF-BB. In a preferred embodiment the second container contains rhPDGF-BB in acetate solution of about 15 mM to about 25 mM, preferably about 20 mM, at a pH of about 5.5 to 6.5.
The amount of PDGF in the second container may change depending on the intended application. The total amount of PDGF in the second container may be about 1 ug to about 50 mg, about 10 ug to about 25 mg, about 100 ug to about 10 mg, and about 250 ug to about 5 mg, or any specific amount within these ranges. In some embodiments, PDGF is present in the solution in a concentration ranging from about 0.01 mg/ml to about 10 mg/ml, from about 0.05 mg/ml to about 5 mg/ml, or from about 0.1 mg/ml to about 1.0 mg/ml or any specific concentration within these ranges. In other embodiments, PDGF is present in the solution at any one of the following concentrations: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.2 mg/ml; about 0.25 mg/ml; about 0.3 mg/ml; about 0.35 mg/ml; about 0.4 mg/ml; about 0.45 mg/ml; about 0.5 mg/ml, about 0.55 mg/ml, about 0.6 mg/ml, about 0.65 mg/ml, about 0.7 mg/ml; about 0.75 mg/ml; about 0.8 mg/ml; about 0.85 mg/ml; about 0.9 mg/ml; about 0.95 mg/ml; or about 1.0 mg/ml.
The following examples will serve to further illustrate the present invention without, at the same time, however, constituting any limitation thereof. On the contrary, it is to be clearly understood that resort may be had to various embodiments, modifications and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the invention. Example 1 describes a study of vertical ridge augmentation in the mandible of the dog. Example 2 describes a study describes a study of vertical ridge augmentation in the maxilla of humans.
EXAMPLE 1
Method of Vertical Ridge Augmentation in Dogs using rhPDGF-BB and a Deproteinized Bovine Bone Block Alone or in Conjunction with a Resorbable Membrane
The principal aims of this study were: 1) To clinically and radiographically evaluate the potential of utilizing rhPDGF-BB and a deproteinized bovine bone block in conjunction with a resorbable membrane in vertical ridge augmentation; 2) To clinically and histologically evaluate the role of a resorbable membrane in bone regeneration mediated by rhPDGF-BB; 3) To evaluate clinically, radiographically and histologically the safety and efficacy of using rhPDGF and a bone block in the absence of membranes to treat vertical bone defects with regard to biocompatibility, osteoconductivity, osteoinductivity, degradability and substitution; 4) To analyze histologically the healing pattern in the test sites; and, 5) To evaluate the bone to implant contact (BIC) of the regenerated bone on two different implant surfaces.
This was an open-labeled, prospective, controlled study using the split-mouth method, comparing in the same animal, the clinical, radiographic and histological outcome in terms of vertical ridge augmentation in artificially created alveolar deficient ridges. The test sites were divided in three distinct groups, each of which was compared with each other.

    GROUP 1: 4 sites received the combination of a deproteinized bovine bone block (Bio-Oss Block, Geistlich biomaterials), rhPDGF-BB (BioMimetic Therapeutics) and a resorbable membrane (Bio-Gide, Geistlich biomaterials) (FIG. 1).
    GROUP 2: 4 sites received the combination of a deproteinized bovine bone block and rhPDGF-BB (FIG. 2).
    GROUP 3: 4 sites received the combination of a deproteinized bovine bone block and a resorbable membrane (FIG. 3).


In addition, two titanium implants (Nobel Biocare, MKIII, 3.3×10 mm) were inserted (mesially and distally) at baseline in all sites. The two implants differed in surface characteristics being a Machined and a Ti-Unite. At 4 months post-op, a biopsy of the inserted implants with their surrounding tissue was extracted for examination.
The test sites were monitored by means of radiographic evaluation at the preliminary procedure, at baseline, and at the re-entry surgery.
Animal randomization: In order to evaluate each test group an equal number of times with every other one, the following combinations were applied. Two dogs were evaluated in each condition.







TABLE 1







Combinations Tested in Animals










SIDE










DOG
RIGHT
LEFT





1
T1
T2


2
T1
T2


3
T1
T3


4
T1
T3


5
T2
T3


6
T2
T3





T1: Bio Block + PDGF + Bio gide


T2: Bio Block + PDGF


T3: Bio Block + Bio gide


Two dogs received: T1 vs T2, two dogs received: T1 vs T3, and two dogs received: T2 vs T3.






Animal inclusion criteria: A total of 6 dogs satisfying the following inclusion criteria were included in the study: 1) Minimum age of 8-9 months in order to have reached the correct bone maturity; 2) Absence of primary dentition; and, 3) Weight at baseline >25 kg.

Experimental Procedures

Preliminary procedures. Oral prophylaxis utilizing hand and ultrasonic instrumentation was performed 2 weeks prior to baseline and 2 weeks prior to experimental procedures
The following baseline measurements were performed after anesthesia: 1. Intraoral photographs of the defect area (optional); 2. Mesial-distal, bucco-lingual and apico-coronal dimensions of the bone defect; and, 3. Distance from the implant shoulder to the bone crest when inserted
Surgical Procedures (B1)
Baseline Procedure; Tooth Extraction and Creation of the Defect
After achievement of general and local anesthesia, a radiographic evaluation was performed. An intrasulcular incision was traced in the posterior region of the mandible both in the right and the left side following the first bicuspid up to the first molar. A mesial releasing incision was traced mesial to the first bicuspid. A distal releasing incision was performed mesial to the first molar. A full thickness flap was elevated and the four premolars extracted. In the same area a vertical defect was artificially created by means of diamond burs along the posterior region of the mandible in order to mimic a deficient alveolar ridge. The defect had the following dimensions; 30 mm in a disto-mesial direction and 7 mm in an apico-coronal direction. The height depended on the topography of the inferior alveolar nerve. The width (bucco-lingual) was the full width of the mandible and thus varied somewhat depending upon the natural width of the animal's mandible. Flaps were sutured over the alveolar crest with interrupted 4/0 silk sutures. Animals were administered the standard post-surgical infection control (Amoxicillin clavulanic acid 2 gm/daily and nimesulide 100 mg every 12 hours for three days). A healing period of three months was required prior to the second surgery.
Second Surgical Procedure/Test Procedure; TI (4 sites)
After achievement of general and local anesthesia, a radiographic evaluation was performed. A crestal incision was traced from mesial to distal, extending distal to the first molar. The buccal and lingual/palatal flap was elevated full thickness to expose the alveolar crest. Excessive soft connective tissue was discarded. Cortical perforations were performed with a 2 mm diameter diamond round bur to expose the medullary spaces and allow bleeding. Intra-operative measurements were then taken. rhPDGF-BB (available in a liquid form) was added under suction to the bovine block in order for the block to become soaked due to its porous characteristics. This was performed by placing the bovine block in a 50 ml plastic sterile syringe, containing the liquid rhPDGF-BB to soak the permeable block under pressure. The block was left in the syringe filled with rhPDGF for approximately 10 minutes.
In the present investigation, a bone block of dimensions 2 cm×1 cm×1 cm was soaked in a solution of rhPDGF at a concentration of 0.3 mg/ml under suction using a large bore syringe. The theoretical void volume of the bone block was calculated as 1.56 ml Actual saturation of the block with a dye solution occurred at 1.67 ml. Accordingly, the total amount of rhPDGF in the block was about (0.3 mg/ml) (1.67 ml) =0.501 mg. During the surgery, these blocks were trimmed to fit within the bone defects so the final size may have varied by up to about 30% when compared to the original size.
In the present investigation, collagen membranes were used. These membranes must be wetted in order to conform properly to the surgical site. In this study, the collagen membranes were saturated with a solution containing 0.3 mg/ml of rhPDGF prior to implantation into the surgical site.
The bone was then placed onto the alveolar bone in the area of the residual bone defect, and stabilized by means of two titanium implants, which perforated the block first and next the cortical mandibular bone. The two titanium implants (Nobel Biocare, MKIII 3.3×10 mm, machined and Ti Unite) were inserted following the standard Branemark protocol in a distal and mesial position allowing a minimum distance of 10 mm between the two. Next, the resorbable membrane (Bio Gide, 30×40 mm) soaked in the rhPDGF solution was added to cover the filling materials and the implants.
It is to be understood that other attachment means may be employed as commonly known to one of ordinary skill in the art. In another embodiment, no attachment means are required when the block is press-fit into the recipient space.
The flaps were closed with internal horizontal mattress sutures prior to the interrupted sutures to ensure primary passive closure of the tissue. If closure was not achieved without further mobilization of the buccal flap, then the buccal full thickness flap was further extended in an apical direction by a periosteal incision. 5-0 Gore-Tex sutures were employed. Buccal and lingual photographs were taken following completion of flap closure in addition to a radiographic evaluation.
Test Procedure; T2 (4 sites)
The employed surgical technique was identical to the one described above (T1) except for the omission of the resorbable membrane.
Test Procedure; T3 (4 sites)
The employed surgical technique was identical to the one described above (T1) except for the omission of rhPDGF-BB.
Animal Sacrifice: (B2)
The six animals were sacrificed 4 months after the test (second) surgical procedure to allow the healing process to occur. Buccal and lingual photographs were taken. Re-entry procedure; mesio-distal biopsy of the test and control sites; (6 dogs). After achievement of general and local anesthesia, a radiographic evaluation was executed. A full block section of the mandible was taken, placed into a sterile container with 10% formalin solution and evaluated histologically.










Time Line




















Results

Both groups receiving rhPDGF exhibited better soft tissue and also hard tissue healing when compared to the other test group without rhPDGF. Clinically and radiographically significant amounts of vertical ridge augmentation was achieved in 7 of 8 sites that received PDGF whereas only 1 of 4 sites had significant bone regeneration in the absence of PDGF. (FIGS. 1 to 3 provide a summary of the radiographic results obtained for the three treatment groups.) The soft tissues healed uneventfully in all but one site that received PDGF. In contrast, all but one site experienced soft tissue dehiscenses and infection in the absence of PDGF. The presence of the membrane did not appear to improve the outcome. That is, PDGF exhibited beneficial effects even in the absence of a membrane. Thus, the use of PDGF appears to eliminate the need to perform GBR.
The combination of rhPDGF and the deproteinized bone block and the presence or absence of a resorbable membrane is useful for treating defects in bone, particularly in the mandible or maxilla, and provides a means to augment the vertical ridge for insertion of metallic implants.
EXAMPLE 2
Sinus Elevation to Stimulate Bone Formation in a Maxillary Osseous Defect
The objective of this study was to evaluate the clinical utility of rhPDGF-BB in combination with β-TCP or other approved bone void filling matrices, for voids or gaps in the maxilla or mandible that are not intrinsic to the stability of the bony structure in accordance with standard clinical practice which included the use of ancillary bone augmentation materials.
Dosage and Method of Administration: All treatment kits contained 0.25 gm of (β-TCP (250-1000 micron particle size) and 0.5 mL sodium acetate buffer solution containing either 0.3 mg/mL rhPDGF-BB (Group I), or 1.0 mg/mL rhPDGF-BB (Group II). Following proper preparation of the surgical site, to receive the PDGF enhanced matrix, the solution was mixed with the β-TCP or other approved bone void filler(s) in a sterile container, such that the graft material was fully saturated. The hydrated graft was carefully packed into the osseous defect. In some cases the filled defect was covered with a resorbable collagen barrier membrane as commonly performed with periodontal surgeries. The tissue flaps were then replaced and secured with interdental sutures to achieve complete coverage of the surgical site.
Summary of Safety Results; There were no device related adverse events or serious adverse events experienced during the study. One subject was discontinued from the study due to non-compliance. No subject discontinued participation in the study due to an adverse event. The safety analysis did not identify any increased safety risk for either concentration of rhPDGF-BB with any of the approved matrices.
Summary of Performance Results: The effectiveness and safety outcomes of GEM 21S therapy were confirmed by the investigator's clinical utility assessments. Improvement in clinical attachment level, periodontal probing depth (PD) and bone fill (>3 mm) was seen in both treatment groups at 6 months post-periodontal surgery. The study results found that 100% of the patients in both rhPDGF-BB treatment groups exhibited an “excellent” outcome. In summary, rhPDGF-BB in combination with approved bone void filling matrices was shown to achieve clinical and radiographic effectiveness in patients six months post-surgery for the treatment of all types of defects, including: periodontal osseous defects, deficient maxillary alveolar ridge height, osseous defects associated with implants and extraction sockets. The use of ancillary bone grafting materials did not alter the benefits of the device of rhPDGF+β-TCP (also called GEM 21S (Biomimetic Therapeutics, Inc., Franklin, Tenn.).
Conclusions: It is concluded from this study that rhPDGF-BB in combination with β-TCP or other approved bone void filling matrices, for voids or gaps in the maxilla or mandible that are not intrinsic to the stability of the bony structure is a safe and clinically beneficial treatment modality for various oral and maxillofacial applications, including extraction sockets, sinus elevation, and ridge augmentation.
Discussion and Overall Conclusions: rhPDGF-BB (0.3 or 1.0 mg/ml) in combination with β-TCP was shown to be safe and clinically useful in this blinded bridging clinical trial (case series) in subjects with general bone defects. The clinical benefit of the treatment modalities was observed in all types of defects, including one, two and three wall defects, as well as circumferential defects. In addition, the materials used in the study were demonstrated to be clinically useful in extraction sockets, sinus elevations, ridge augmentations, and peri-implant defects. The study results demonstrated that rhPDGF-BB (0.3 or 1.0 mg/ml) in combination with β-TCP regenerated bone and soft tissue in the treatment of periodontal osseous defects, sinus elevation, implant and extraction socket. There were no adverse events attributable to the study device and the device was found to be safe.
It is concluded from this study that rhPDGF-BB (0.3 or 1.0 mg/ml) in combination with β-TCP is a safe and clinically beneficial treatment modality for a wide range of oral and maxillofacial applications, including extraction sockets, sinus elevation, and ridge augmentation. In addition rhPDGF-BB (0.3 or 1.0 mg/ml) was shown to be compatible with grafting materials such as xenografts, allografts, and/or bioresorbable guided tissue regeneration (GTR) membranes.
Sinus Elevation Studies
Subject 10-06 was treated for insufficient alveolar ridge height with a sinus augmentation procedure in the left posterior maxilla. A lateral window approach was utilized to place the graft of 0.3 mg/ml rhPDGF-BB in freeze dried bone allograft (FDBA) and xenograft (BioOss particulate material). Following placement of the graft, a collagen barrier membrane was placed over the lateral access window. The soft tissue flap was closed primarily with sutures and study medication containment within the treatment site, and soft tissue closure, were rated excellent by the investigator. Soft tissue healing was rated as excellent at all follow-up visits. Sutures were removed one week post-surgery. Radiographs obtained at 2 and 6 months post-surgery demonstrated normal healing with no sign of pathology. Additionally, histologic evaluation of a bone core sample obtained 6 months post-surgical, at the time of implant surgery demonstrated graft particles in new bone with extensive osteoid and new bone bridging the graft particles. At 6 months post-surgery, clinical utility assessment of treatment outcome was rated by the investigator as excellent for efficacy, safety and overall assessment; patient compliance and patient acceptance were rated as good.
Subject 10-09 was treated for insufficient alveolar ridge height (bilateral) in the posterior maxilla. Treatment consisted of a sinus floor augmentation with 0.3 mg/ml rhPDGF-BB in FDBA and xenograft. Prior to flap closure a collagen barrier membrane was placed over the sinus “window”. Study medication containment within the lesion and soft tissue closure were rated excellent by the investigator. Soft tissue healing was rated initially as good and then excellent from one month post-surgery throughout the six month observation period. Sutures were removed at 2 weeks post-surgery. A radiograph was obtained immediately post-surgery and 3 months post-surgery for the left side and demonstrated increased vertical bone height of the sinus floor. This subject failed to comply with follow-up Visits 6 and 7 (18 and 24 weeks post-surgery) and did not complete the study; therefore clinical utility assessment of treatment outcome was not rated.
Subject 10-05 presented for treatment of insufficient vertical bone height (near pneumatization of the sinus) in the posterior maxilla. Treatment consisted of a sinus augmentation procedure utilizing a lateral sinus approach. The deficient ridge was augmented with 1.0 mg/ml rhPDGF-BB in FDBA and xenograft. The lateral window was covered, prior to flap closure, with a collagen barrier membrane. Study medication containment within the lesion was rated excellent and soft tissue closure was rated as good by the investigator. Soft tissue healing was rated as excellent on follow-up visits except visit 3 which was rated as good. Sutures were removed 1 and 3 weeks post-surgery. Radiographs obtained at 3, 4, and 6 months post-surgery demonstrated increased vertical height of the sinus floor with no sign of pathology. Additionally, increased bone trabeculation within the grafted site was observed and may be indicative of bone maturation within the grafted region. Bone cores obtained from the grafted site at the time of implant surgery reveal extensive new bone formation throughout the site with graft particles surrounded by new bone and osteoid. Bridging of the particles by bone and/or osteoid was also observed throughout the augmented site. Six months post-surgery, clinical utility assessment of treatment outcome was rated as excellent for efficacy, safety, patient acceptance and overall assessment; patient compliance was rated as good.
All patents, publications and abstracts cited above are incorporated herein by reference in their entirety. It should be understood that the foregoing relates only to preferred embodiments of the present invention and that numerous modifications or alterations may be made therein without departing from the spirit and the scope of the present invention as defined in the following claims.

## Claims

1. A method of enhancing bone augmentation in a subject comprising applying a composition consisting of a biocompatible matrix having incorporated therein a solution consisting of platelet derived growth factor (PDGF) in a buffer to a site for desired bone augmentation in the subject;
wherein the biocompatible matrix consists of collagen and a porous calcium phosphate;
wherein the calcium phosphate consists of particles in a range of about 75 micron to about 5000 micron in size;
wherein the calcium phosphate comprises interconnected pores; and
wherein the biocompatible matrix is flowable, moldable and/or extrudable.

2. The method of claim 1, wherein the calcium phosphate consists of particles in a range of about 100 microns to about 5000 microns in size.

3. The method of claim 1, wherein the calcium phosphate consists of particles in a range of about 100 microns to about 300 microns in size.

4. The method of claim 1, wherein the calcium phosphate consists of particles in a range of about 250 microns to about 1000 microns in size.

5. The method of claim 1, wherein the calcium phosphate consists of particles in a range of about 1000 microns to about 2000 microns in size.

6. The method of claim 1, wherein the calcium phosphate is resorbable such that the calcium phosphate is resorbed within one year of being implanted.

7. The method of claim 1, wherein the calcium phosphate has a porosity that facilitates osteoinduction, osteoconduction, or osteoinduction and osteoconduction.

8. The method of claim 1, wherein the calcium phosphate has macroporosity.

9. The method of claim 1, wherein the calcium phosphate has a porosity greater than 25%.

10. The method of claim 1, wherein the calcium phosphate has a porosity greater than 50%.

11. The method of claim 1, wherein the calcium phosphate is β-tricalcium phosphate.

12. The method of claim 1, wherein the PDGF is recombinant PDGF.

13. The method of claim 12, wherein the recombinant PDGF comprises recombinant human PDGF-BB.

14. The method of claim 13, wherein the recombinant human PDGF-BB (rhPDGF-BB) comprises at least 65% intact rhPDGF-B.

15. The method of claim 1, wherein the solution consists of PDGF at a concentration in a range of about 0.01 mg/ml to about 10 mg/ml in a buffer.

16. The method of claim 1, wherein the solution consists of PDGF at a concentration in a range of about 0.05 mg/mL to about 5 mg/mL in a buffer.

17. The method of claim 1, wherein the solution consists of PDGF at a concentration in a range of about 0.1 mg/mL to about 1.0 mg/mL in a buffer.

18. The method of claim 1, wherein the solution consists of PDGF at a concentration of about 0.3 mg/mL in a buffer.

19. The method of claim 1, wherein the PDGF comprises PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, PDGF-DD, or a derivative thereof.

20. The method of claim 1, wherein the PDGF comprises one or more fragments of the B chain, wherein the fragments are selected from the group consisting of: the amino acid sequences 1-31 (SEQ ID NO: 1), 1-32 (SEQ ID NO: 2), 33-108 (SEQ ID NO: 3), 33-109 (SEQ ID NO: 4), and 1-108 (SEQ ID NO: 5) of the B chain.

21. The method of claim 1, wherein the biocompatible matrix consists of collagen and a porous calcium phosphate, wherein the calcium phosphate consists of particles in a range of about 100 microns to about 5000 microns in size, wherein the calcium phosphate has a porosity greater than 25%, wherein the calcium phosphate is β-tricalcium phosphate, wherein the PDGF comprises recombinant human PDGF-BB, and wherein the solution consists of PDGF at a concentration in a range of about 0.01 mg/ml to about 10 mg/ml in a buffer.

22. The method of claim 21, wherein the PDGF is present in the solution at a concentration of about 0.1 to about 1.0 mg/ml.

23. The method of claim 21, wherein the PDGF is present in the solution at a concentration of about 0.3 mg/ml.

24. The method of claim 21, wherein the calcium phosphate consists of particles in a range of about 100 microns to about 300 microns in size.

25. The method of claim 21, wherein the calcium phosphate consists of particles in a range of about 250 microns to about 1000 microns in size.

26. The method of claim 21, wherein the calcium phosphate consists of particles in a range of about 1000 microns to about 2000 microns in size.

27. The method of claim 21, wherein the calcium phosphate has a porosity that facilitates osteoinduction, osteoconduction, or osteoinduction and osteoconduction.

28. The method of claim 1, further comprising administering a bisphosphonate to the subject.

29. The method of claim 1, wherein the site is a maxillofacial site and a maxillofacial bone is augmented.

30. The method of claim 29, wherein the maxillofacial site is an alveolar ridge, a bone defect, a wall of the maxillary sinus, or an extraction socket.

31. The method of claim 29, wherein the maxillofacial site is located in a maxilla or a mandible.

32. The method of claim 1, wherein the subject is diabetic.

33. The method of claim 1, wherein the subject is an osteoporotic subject.

34. The method of claim 1, wherein the subject is a smoker.

35. The method of claim 1, wherein the subject is a steroid user.

36. The method of claim 1, wherein the method facilitates achievement of a stable osseointegrated implant.

37. The method of claim 1, wherein the method comprises repair of an extraction socket.

38. The method of claim 1, further comprising covering the composition with a bioresorbable membrane.

39. The method of claim 38, wherein the bioresorbable membrane comprises collagen.

40. The method of claim 38 or 39, wherein the bioresorbable membrane comprises PDGF.